AOTMiT: Transparency Council on AD and chronic migraine, among others

Agenda:

1. Evaluation of the drug Qinlock (ripretinibum)
   
   • Drug program: "Treatment of patients with advanced gastrointestinal submucosal tumor (GIST)".
   • ICD-10: C15, C16, C17, C18, C20, C48

1. Evaluation of the drug Ebglyss (lebrikizumabum)
   
   • Drug program B.124: "Treatment of patients with atopic dermatitis".
   • ICD-10: L20

1. Evaluation of the drug Vyepti (eptinezumabum)
   
   • Drug program B.133: "Prophylactic treatment of patients with chronic migraine".
   • ICD-10: G43

1. Evaluation of the drug Remsima (infliximabum) under drug programs:
   
   • B.33: "Treatment of patients with active rheumatoid arthritis and juvenile idiopathic arthritis."
   • B.35: "Treatment of patients with psoriatic arthritis (Psoriatic arthritis)".
     • ICD-10: L40.5, M07.1, M07.2, M07.3
   • B.36: "Treatment of patients with active ankylosing spondylitis (AS)".
     • ICD-10: M45
   • B.47: "Treatment of patients with moderate to severe plaque psoriasis".
     • ICD-10: L40.0
   • B.32: "Treatment of patients with Crohn's disease".
     • ICD-10: K50
   • B.55: "Treatment of patients with ulcerative colitis (UC)."
     • ICD-10: K51

1. Opinion on continuation of docetaxel reimbursement
   
   • Indication: malignant tumor of the esophagus
   • ICD-10: C15
   • Scope: treatment of esophageal adenocarcinoma patients with radical and palliative chemotherapy regimens
   • Reimbursement availability category: chemotherapy drug for an indication defined by a clinical condition.

Source: AOTMIT